Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Jian‐Yu Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5841-5282; OpenAlex author ID A5101408137. Sources: OpenAlex.

Their work

Papers
37 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
78
Papers, trials and grants by year

2014: 1 paper · 2015: 3 papers · 2016: 5 papers · 2017: 4 papers · 2018: 1 paper · 2019: 4 papers · 2020: 3 papers · 2021: 5 papers · 2022: 4 papers · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 3 papers

Papers 37

  1. A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing… Co-author DOI 10.1158/1078-0432.ccr-25-3359↗
  2. Retraction: Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.28909↗
  3. L-Lactate reprograms tumor-associated macrophages to drive pancreatic cancer progression via BCL3 lactylation Co-author DOI 10.64898/2026.03.06.710237↗
  4. Construction and validation of immunogenic cell death-related molecular clusters, signature, and immune landscape in pancreatic cancer. Co-author DOI 10.1007/s10238-024-01533-7↗
  5. The lncRNA LINC01605 promotes the progression of pancreatic ductal adenocarcinoma by activating the mTOR signaling pathway. Co-author DOI 10.1186/s12935-024-03440-z↗
  6. Analysis of cuproptosis-related lncRNA signature for predicting prognosis and tumor immune microenvironment in pancreatic cancer. Co-author DOI 10.1007/s10495-023-01843-3↗
  7. Increased SPRY1 expression activates NF-κB signaling and promotes pancreatic cancer progression by recruiting neutrophils and macrophages through CXCL12-CXCR4 … Co-author DOI 10.1007/s13402-023-00791-z↗
  8. IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer. Co-author DOI 10.1007/s13402-022-00670-z↗
  9. SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215693↗
  10. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Co-author DOI 10.1111/cpr.13237↗
  11. Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/ph15111336↗
  12. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis. Co-author DOI 10.1002/1878-0261.12970↗
  13. CD74 promotes perineural invasion of cancer cells and mediates neuroplasticity via the AKT/EGR-1/GDNF axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2021.03.016↗
  14. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-020-20447-y↗
  15. ERO1L Promotes Hepatic Metastasis through Activating Epithelial-Mesenchymal Transition (EMT) in Pancreatic Cancer. Co-author DOI 10.1155/2021/5553425↗
  16. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic duc… Co-author DOI 10.1186/s13059-020-02222-w↗
  17. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  18. Molecular markers associated with perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2020.11866↗
  19. Endoplasmic Reticulum stress-dependent expression of ERO1L promotes aerobic glycolysis in Pancreatic Cancer. First author DOI 10.7150/thno.45124↗
  20. Transcription factor NFAT5 contributes to the glycolytic phenotype rewiring and pancreatic cancer progression via transcription of PGK1. Co-author DOI 10.1038/s41419-019-2072-5↗
  21. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling in a GAB… Co-author DOI 10.1136/gutjnl-2018-317479↗
  22. DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2019/8656282↗
  23. SFRP4 is a prognostic marker and correlated with Treg cell infiltration in pancreatic ductal adenocarcinoma. Co-author PMID 30906634↗
  24. Decreased expression of USP9X is associated with poor prognosis in Chinese pancreatic ductal adenocarcinoma patients. Co-author DOI 10.3892/ol.2018.8452↗
  25. Integrated expression profiling of potassium channels identifys KCNN4 as a prognostic biomarker of pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2017.10.072↗
  26. Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance. Co-author DOI 10.1016/j.canlet.2017.02.036↗
  27. The role of Dickkopf-1 as a potential prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/15384101.2017.1356510↗
  28. High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with Cell Cycle and Cell Proliferation. Co-author DOI 10.7150/jca.20086↗
  29. Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep33535↗
  30. Efficacy of Neo-Adjuvant Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma: A PRISMA-Compliant Meta-Analysis and Systematic Review. Co-author DOI 10.1097/md.0000000000003009↗
  31. CXCL12-CXCR7 axis contributes to the invasive phenotype of pancreatic cancer. Co-author DOI 10.18632/oncotarget.11330↗
  32. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.6772↗
  33. Elevated expression of CTHRC1 predicts unfavorable prognosis in patients with pancreatic ductal adenocarcinoma. Co-author PMID 27648368↗
  34. Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep10575↗
  35. Corrigendum: Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep15869↗
  36. High expression of DDR1 is associated with the poor prognosis in Chinese patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-015-0202-1↗
  37. MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer. Co-author PMID 25520858↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongwei Sun · 29 shared papers, 2014–2026 · strength 2.69
  2. Minwei Yang · 24 shared papers, 2015–2026 · strength 2.63
  3. Yan‐Miao Huo · 26 shared papers, 2015–2026 · strength 2.57
  4. Xueliang Fu · 22 shared papers, 2015–2026 · strength 2.21
  5. Rong Hua · 24 shared papers, 2014–2024 · strength 2.08
  6. Dejun Liu · 17 shared papers, 2015–2022 · strength 1.52
  7. Shu‐Heng Jiang · 14 shared papers, 2015–2026 · strength 1.45
  8. Junfeng Zhang · 13 shared papers, 2016–2026 · strength 1.42
  9. Zhigang Zhang · 13 shared papers, 2015–2026 · strength 1.06
  10. Jia-Hao Zheng · 6 shared papers, 2022–2026 · strength 1.01
  11. Zong‐Hao Duan · 4 shared papers, 2022–2026 · strength 0.76
  12. Ruizhe He · 7 shared papers, 2019–2023 · strength 0.76
  13. Hong‐Fei Yao · 5 shared papers, 2022–2024 · strength 0.73
  14. Junfeng Zhang · 8 shared papers, 2014–2024 · strength 0.72
  15. Wei Chiang Liu · 7 shared papers, 2016–2022 · strength 0.66
  16. Jian Yang · 4 shared papers, 2022–2023 · strength 0.54
  17. Yu-Heng Zhu · 3 shared papers, 2022–2024 · strength 0.47
  18. Qin-Yuan Jia · 3 shared papers, 2022–2024 · strength 0.47
  19. Yong-Wei Sun · 2 shared papers, 2026 · strength 0.46
  20. Li-Peng Hu · 5 shared papers, 2017–2022 · strength 0.45
  21. Wei Liu · 4 shared papers, 2016–2024 · strength 0.41
  22. Pei‐Xuan Ji · 2 shared papers, 2022–2026 · strength 0.38
  23. Hong Li · 2 shared papers, 2021–2026 · strength 0.37
  24. Yongsheng Jiang · 4 shared papers, 2019–2022 · strength 0.34
  25. Ping Lu · 3 shared papers, 2020–2022 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.